Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 71,621 | 67,449 | 121,966 | 67,271 | 37,598 |
| Marketable Securities | 0 | 5,002 | 0 | 35,162 | 96,190 |
| Receivables | 40,415 | 39,197 | 30,830 | 17,456 | 6,875 |
| Inventories | 48,175 | 38,838 | 24,735 | 18,118 | 8,353 |
| TOTAL | $167,662 | $156,264 | $186,818 | $142,596 | $152,212 |
| Non-Current Assets | |||||
| PPE Net | 5,562 | 5,971 | 5,516 | 6,627 | 6,707 |
| Intangibles | 121,780 | 132,623 | 143,466 | 154,309 | 0 |
| Other Non-Current Assets | 28,056 | 27,744 | 8,722 | 829 | 232 |
| TOTAL | $155,398 | $166,338 | $157,704 | $161,765 | $6,939 |
| Total Assets | $323,060 | $322,602 | $344,522 | $304,361 | $159,151 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 15,102 | 0 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 2,290 | 11,565 | 4,606 | 8,924 | 3,117 |
| Accrued Expenses | 48,166 | 36,347 | 27,991 | 19,041 | 8,873 |
| Other current liabilities | 1,089 | 20,276 | 2,658 | 1,987 | 322 |
| TOTAL | $100,443 | $95,193 | $73,621 | $79,040 | $28,207 |
| Non-Current Liabilities | |||||
| Long Term Debt | 217,006 | 190,932 | 187,075 | 88,067 | 87,021 |
| Other Non-Current Liabilities | 35,226 | 40,991 | 35,121 | 30,198 | 3,533 |
| TOTAL | $252,232 | $234,191 | $225,714 | $130,090 | $97,183 |
| Total Liabilities | $352,675 | $329,384 | $299,335 | $209,130 | $125,390 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 153,940 | 140,454 | 137,289 | 135,524 | 59,765 |
| Common Shares | 15 | 14 | 14 | 13 | 6 |
| Retained earnings | -671,861 | -617,025 | -554,770 | -460,110 | -337,385 |
| Other shareholders' equity | -25 | -25 | -23 | -31 | 6 |
| TOTAL | $-29,615 | $-6,782 | $45,187 | $95,231 | $33,761 |
| Total Liabilities And Equity | $323,060 | $322,602 | $344,522 | $304,361 | $159,151 |